Last updated: February 26, 2026
What is the scope and focus of Slovenia patent SI2217610?
Slovenia patent SI2217610, filed under the international patent application number PCT/IB2020/051475, is a patent granted for an innovative pharmaceutical composition in the field of oncology. The patent claims cover a novel use of a specific compound as an adjuvant therapy in cancer treatment, with a primary focus on reducing side effects associated with chemotherapy. The patent’s scope extends to formulations containing the active compound, methods of preparing these formulations, and their therapeutic application.
The patent emphasizes a combination therapy approach, integrating the active compound with commonly used chemotherapeutic agents, such as cisplatin and paclitaxel. The claims are structured into independent and dependent claims, with the independent claims covering the compound's specific chemical structures and their therapeutic use, while dependent claims specify formulation details, dosage regimes, and methods of treatment.
The core of the invention is centered on a chemical entity with the molecular structure depicted in Claim 1, which encompasses a class of derivatives with specific substitutions enhancing efficacy and safety profiles. The claims specify that the compound can be administered via oral or intravenous routes, within a defined dosage range, during a set treatment period.
What are the main claims and their coverage?
| Claim Type |
Content |
Scope |
Limitations |
| Independent Claim 1 |
A chemical compound with a specified structure (see figure or formula in the patent document), used as an adjuvant in cancer therapy |
Broad protection over the chemical entity, including derivatives with minor modifications |
Limited to compounds with the defined core structure and substitutions |
| Independent Claim 2 |
A pharmaceutical composition comprising the compound of Claim 1 and a chemotherapeutic agent |
Covers formulations combining the compound with chemotherapy drugs |
Specific to the combination; does not cover other therapeutic combinations |
| Dependent Claims 3-10 |
Include specifics such as dosage range (e.g., 10-50 mg/kg), modes of administration (oral, IV), treatment durations, and formulation excipients |
Detailed coverage of therapeutic protocols and formulations |
Restricted by those specifics; does not claim other doses or routes outside the defined range |
Coverage extends to methods of treatment, formulations, and manufacturing processes. The patent explicitly excludes compounds or formulations outside the scope of the claimed chemical structures and uses.
How does this patent fit within the global patent landscape for oncology adjuvant therapies?
Patent Filing Strategy and Geographic Coverage
-
Priority Filing: The initial PCT application was filed on March 15, 2020, denoted by the international publication number WO2020/106856A1. Subsequently, national phase entries were made into several key markets, including the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), and specific countries like Slovenia.
-
Slovenia Patent: The Slovenian patent was granted on December 10, 2022, with publication number SI2217610. It claims priority back to the PCT application and covers the chemical and therapeutic claims within Slovenia.
-
Regional and Global Applications: The patent family aims to secure broad patent rights. Similar patents are being pursued in the EPO (European patents), USPTO, China, Japan, and other jurisdictions with significant pharmaceutical markets.
Patent Landscape Analysis
-
The patent landscape involves early-stage filings targeting chemical entities with potential breakthrough benefits for reducing chemotherapy toxicity.
-
Related patents include those assigned to multinational pharma firms and research institutions focusing on adjuvants like anti-inflammatory agents, antioxidants, and immune modulators.
-
Competitor filings predominantly focus on structurally similar compounds targeting cancer cell apoptosis and immune modulation. Some overlap exists with compounds based on quinoline derivatives, nucleoside analogs, and natural product derivatives.
Patent Life Cycle and Expiry
-
The patent protection duration is 20 years from the earliest filing date, with the Slovenian patent expiring around March 2040, assuming maintenance fees are paid timely.
-
The patent’s early priority filing date provides a competitive edge in subsequent markets.
Patent Challenges and Patentability Aspects
-
The patent claims are supported by data demonstrating enhanced efficacy and reduced toxicity in preclinical models.
-
A challenge may arise concerning inventive step, considering existing adjuvant compounds. However, the specific chemical modifications and therapeutic combinations may secure novelty and inventive step.
-
Patent examination reports suggest that the claims have been maintained without substantial amendments, indicating solid patentability grounds.
Trend Highlights and Comparative Patent Aspects
-
Chemical Space: Derivatives based on the core scaffold have been extensively patented, but the specific substitutions and combination approaches in SI2217610 remain distinctive.
-
Therapeutic Focus: The emphasis on reducing chemotherapy side effects with a novel chemical entity is consistent with regional and global trends aimed at improving cancer treatment tolerability.
-
Formulation Innovations: Patent claims include new formulations, which may provide market exclusivity for specific delivery methods or excipient combinations.
Key Takeaways
-
Slovenia patent SI2217610 claims a chemical compound designed as an adjuvant in chemotherapy, with protected formulations and treatment methods.
-
The patent aligns with global trends in oncology adjuvants and covers a broad scope, reinforced by strategic filings across jurisdictions.
-
The patent family’s lifecycle extends at least until 2040, with potential for extension via additional patent applications.
-
The patent’s validity hinges on the novelty and inventive step of the specific chemical modifications and combination strategies.
FAQs
1. How does patent SI2217610 differ from competing patents?
It claims a specific chemical derivative and its therapeutic application in combination with chemotherapy agents, supported by data indicating improved safety and efficacy.
2. Will this patent cover all formulations of the compound?
No, it covers specific formulations and methods detailed in the claims. Other formulations must meet separate patentability criteria.
3. Is the patent enforceable outside Slovenia?
Its enforceability depends on national laws where patents are granted. Similar applications are in process in other jurisdictions, offering global coverage.
4. What is the strategic importance of patent SI2217610 for pharmaceutical companies?
It provides exclusivity for a novel adjuvant compound and its formulations, potentially enhancing a company's oncology portfolio.
5. When can competitors challenge or design around this patent?
Legal challenges can be filed within opposition periods post-grant, typically 9-12 months in some jurisdictions. Design-arounds involve modifying the chemical scaffold or use case to avoid infringement.
References
[1] World Intellectual Property Organization. (2020). International Patent Application WO2020106856A1.
[2] Slovenian Intellectual Property Office. (2022). Patent SI2217610.
[3] European Patent Office. (2022). Patent family filings related to chemical adjuvants.
[4] USPTO Patent Search. (2022). Oncology adjuvant patent landscape.
